This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Idenix Pharmaceuticals' CEO Provides Update On IDX184 Clinical Development Program Conference (Transcript)

Idenix Pharmaceuticals, Inc. (IDIX)

Update on IDX184 Clinical Development Program Conference Call

August 16, 2012 08:30 am ET


Daniella Beckman - SVP & CFO

Ron Renaud - President & CEO

Doug Mayers - EVP & CMO

David Standring - EVP & CSO


Geoff Meacham - JPMorgan

Katherine Xu - William Blair

Yaron Werber - Citi

Howard Liang - Leerink Swann

Matt Roden - UBS

Daniel Brims - Brean Murray

Liisa Bayko - JMP

David Friedman - Morgan Stanley

Ying Huang - Barclays

Jim Birchenough - BMO Capital

Mark Schoenebaum - ISI Group

Yaron Werber - Citi



Good day ladies and gentlemen and welcome to the Idenix provides update on IDX184 clinical development conference call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will be given at that time. (Operator Instructions) As a reminder, today’s call is being recorded.

I would now like to turn the conference over to Ms. Daniella Beckman. Ma'am, you may begin.

Daniella Beckman

Thank you. Good morning and welcome to Idenix Pharmaceuticals conference call to discuss the clinical development and status of our lead drug candidate, IDX184. My name is Daniella Beckman and I am the Chief Financial Officer at Idenix.

On this morning’s call is Ron Renaud, President and Chief Executive Officer; Doug Mayers, Chief Medical Officer, who has dialed in remotely and David Standring, Chief Scientific Officer.

Before we begin, I'll review our Safe Harbor statement. Today’s discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of factors that could cause actual results to differ materially.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.54 2.00%
FB $117.76 -0.68%
GOOG $695.63 -0.37%
TSLA $233.06 -3.60%
YHOO $36.09 -1.20%


Chart of I:DJI
DOW 17,752.14 -139.02 -0.78%
S&P 500 2,065.06 -16.37 -0.79%
NASDAQ 4,775.9440 -41.65 -0.86%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs